We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
NewLink Genetics Corporation | NASDAQ:NLNK | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.89 | 0.85 | 0.915 | 0 | 01:00:00 |
Exhibit Number
|
|
Description
|
99.1
|
|
Press Release, dated January 8, 2018, entitled “NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors”
|
99.2
|
|
J.P. Morgan Healthcare Conference Presentation
|
|
NewLink Genetics Corporation
|
|
|
|
|
By:
|
/s/ John B. Henneman III
|
|
John B. Henneman III
|
Its:
|
Chief Financial Officer
|
Exhibit Number
|
|
Description
|
99.1
|
|
Press Release, dated January 8, 2018, entitled “
NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitor
s”
|
99.2
|
|
1 Year NewLink Genetics Chart |
1 Month NewLink Genetics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions